CytoSorbents Corporation announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14-16, 2026. The company's CEO and CFO will engage in a fireside chat and investor meetings to discuss their blood purification technology used in intensive care and cardiac surgery. Their lead product, CytoSorb®, is widely used in over 70 countries and targets life-threatening conditions by removing toxins from blood. The company is also pursuing FDA approval for new devices aimed at reducing bleeding risks during surgery in the U.S. and Canada.
Ahead of Oracle's earnings report, options traders are favoring call options over puts, indicating bullish sentiment and expecting an 11% stock price move. This expectation is influenced by Oracle's history of sharp post-earnings moves, including a n...
VolitionRx presented its Capture-Seq™ technology at the ESMO MAP 2026 conference, demonstrating highly accurate early-stage cancer detection using a novel liquid biopsy method. The technology detected 95% of stage I and II cancers in validation studi...
Cryptocurrency markets saw a general decline with major coins like Bitcoin dropping 2.03% to $77,737 and Ethereum falling 1.66% to $2,457.87. Other notable cryptocurrencies such as Binance Coin, XRP, and Dogecoin also experienced significant decrease...
Alphabet's shares fell 7.46% over the past month, underperforming the Nasdaq despite strong fundamentals like 24.23% revenue growth and robust AI investments. The company leads in search, video, cloud, and AI, with Google Cloud revenue up 82% year-ov...
XStable, a decentralized trading platform for real-world assets, has integrated with the Sui Network to enable on-chain trading of gold, silver, platinum, and foreign exchange pairs. This expansion beyond Solana adds Sui Wallet support and USDC trans...
